Granules India Ltd has unveiled plans to raise funds via preferential issuance of shares worth up to ₹3 billion and warrants valued at approximately ₹14.63 billion. The move aims to strengthen its capital base, support growth initiatives, and enhance long-term financial flexibility for strategic expansion.
Granules India Ltd, a leading pharmaceutical company, has announced a significant fundraising initiative through preferential allotment. The company will issue equity shares and warrants to investors, enabling it to mobilize fresh capital for expansion, debt reduction, and operational strengthening. This step reflects Granules’ proactive approach to sustaining growth momentum in the competitive pharma sector.
Key Highlights
-
Granules to raise up to ₹3 billion through issuance of equity shares on a preferential basis
-
Company to issue warrants worth approximately ₹14.63 billion, providing additional capital inflow potential
-
The fundraising plan is designed to bolster financial flexibility and support strategic investments in manufacturing and R&D
-
Preferential allotment ensures targeted capital raising from select investors, aligning with SEBI regulations
-
The move underscores Granules’ commitment to strengthening its balance sheet and enhancing shareholder value
This capital infusion positions Granules India to accelerate its growth trajectory, expand its global footprint, and reinforce its competitive edge in the pharmaceutical industry.
Sources: BSE India, NSE India, Moneycontrol